Comparative Pharmacology
Head-to-head clinical analysis: OMNIPAQUE 70 versus VASCORAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPAQUE 70 versus VASCORAY.
OMNIPAQUE 70 vs VASCORAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast by increasing the density of blood vessels and organs.
VASCORAY is a fixed combination of iodixanol and calcium sodium edetate. Iodixanol is a nonionic, dimeric, isotonic iodinated contrast medium that increases radiographic contrast by attenuating X-rays. Calcium sodium edetate chelates calcium, potentially reducing contrast-induced nephropathy risk.
1.5-2.0 mL/kg IV for contrast enhanced CT, max 150 mL; intra-arterial: 5-40 mL per injection depending on procedure.
0.5-1.0 mL/kg intravenously as a single dose, not to exceed 5 mL/kg total.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment (up to 20-30 hours in severe dysfunction).
Terminal elimination half-life of 8-12 hours in patients with normal renal function; prolonged in renal impairment.
Renal: 100% unchanged via glomerular filtration. No biliary or fecal elimination.
Primarily renal (90% unchanged), with 10% biliary/fecal.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent